Trends in the use of outcome parameters for respiratory drug research

Substantial success has been realized in the treatment respiratory diseases due to more insight in the mechanisms of disease like inflammatory pathways and new targets for treating these diseases. However, there is a clear discrepancy between the outcome parameters, currently used in clinical studies, and clinical outcome and survival. So, there is an unmet need for additional more sensitive outcome parameters that would assist in understanding the mode of action and subsequent pharmacodynamics effects. The ever rising costs and attrition rate of developing new respiratory drugs, makes it mandatory to increase the performance of clinical trials by using these methods and by more efficient study designs.

Biography

Robert Lins is a Project Director Respiratory Diseases, SGS Clinical Research and is a MD, certified specialist in Internal Medicine, Nephrology and Hypertension with a PhD in Medical Sciences from the University of Antwerp, Belgium. He was a Fellow of the Belgian College of Pharmaceutical Physicians. He has started his activities in Animal Clinical Pharmacology in the Heymans Institute In Gent, Belgium, and is continuously active in the field of Human Clinical Pharmacology. He first studied renal patients and later he founded the SGS Clinical Pharmacology Unit Antwerp, Belgium, where many innovative human pharmacology models were developed for the study of cardiovascular, metabolic, CNS, infectious and respiratory drugs, like bronchial challenge methods, a local bronchial PK model and sputum induction. He has published many articles about Clinical Pharmacology in these different areas of research.

robert@linsconsulting.be